<DOC>
	<DOCNO>NCT01865500</DOCNO>
	<brief_summary>Chronic obstructive pulmonary disease ( COPD ) common disease chronic progressive course . Patients COPD may exacerbations one four time year . Numbers exacerbation important increase morbidity mortality healthcare cost . Systemic corticosteroid ( SC ) recommend management exacerbation COPD well bronchodilator , oxygen antibacterial treatment international guideline . However , still concern systemic corticosteroid use COPD patient older relatively immobilized . In addition , exacerbation rate significantly high group COPD patient , patient need high amount SC order control exacerbation . It result adverse effect osteoporosis bone fracture , thin skin , posterior subcapsular cataract formation , glucose intolerance myopathy . Thus , condition lead clinician seek alternative option . However , study show nebulized steroid ( NS ) effective SC exacerbation COPD optimal NS dose certain . The investigator aim determine optimal NS dose evaluate efficacy safety NS compare SC treatment patient COPD exacerbation require hospitalization .</brief_summary>
	<brief_title>Two Different Dosages Nebulized Steroid Versus Parenteral Steroid Management COPD Exacerbations</brief_title>
	<detailed_description>Study Population One hundred twenty patient moderate severe COPD exacerbation old 40-years-old , smoke history least 10-pack-years require hospitalization include study . COPD diagnosis base clinical evaluation define American Thoracic Society ( ATS ) . The patient exclude presence asthma , allergic rhinitis , atopy systemic disease ( diabetes mellitus hypertension ) ; expose systemic corticosteroid precede month ; use 1,500 microg/d inhale beclomethasone equivalent ; admission intensive care unit ( pH &lt; 7.30 and/or arterial partial pressure carbon dioxide ( PaCO2 ) &gt; 70 mm Hg , and/or arterial partial pressure oxygen ( PaO2 ) &lt; 50 mm Hg despite supplemental oxygen ) ; specific cause exacerbation , pneumonia , pneumothorax , heart failure , diagnose . Study Design The study randomize , double-blind , parallel design trial . The randomization order determine use computer-generated list random number . Eligible patient randomly allocate one three treatment group , , parenteral corticosteroid ( PS ) , 4 mg nebulized budesonide ( NB ) 8 mg NB . The efficacy study medication assess hospitalization , 24 h , 48 h discharge . Patients monitor hospitalization . Patients withdraw study require intubation manage intensive care unit . Treatments Treatment PS group consist methylprednisolone 40 mg ( intravenous ampoule ) ; treatment NB group consist nebulized budesonide suspension ( Pulmicort nebuampul® 0.5 mg/ml ; Astra-Zeneca Pharmaceutical Production ) 10 day . Budesonide give 2 mg twice daily 4 mg twice daily ; methylprednisolone give daily intravenously . Nebulization procedure perform jet nebulizer ( Porta Neb® Ventstream® 1803 ; Medic-Aid ) 80 % output le 5 micron . Patients receive standard treatment nebulized ß-agonist ( salbutamol 3.01 mg ) anticholinergic ( ipratropium bromide 0.5 mg ) combination every 6 hour , intravenous aminophylline ( 0.5 mg/kg/h ) oral intravenous antibacterial discretion attend physician . Supplementary oxygen therapy use maintain oxygen saturation ( SaO2 ) &gt; 90 % . Measurements Patients assess every 12 h acute phase ( H0 H48 ) , hospital discharge . Arterial blood sample take baseline , 24 , 48 h discharge determination PaO2 , PaCO2 , pH , regardless whether patient room air supplementary oxygen . Spirometry ( Sensor Medics , Vmax22 ) carry 15 20 min bronchodilator nebulization ( ß2-agonist ipratropium bromide ) accord ATS standard . Dyspnea assess accord modify Borg scale . Complete blood cell count obtain entry , blood glucose , sodium , potassium measure H0 H48 . Endpoints The primary endpoint ass treatment efficacy change arterial blood gas H0 H24 , H48 discharge . Secondary endpoint include change FEV1 ( forced expiratory volume 1 second ) , dyspnea score , duration hospitalization , occurrence adverse event . An adverse event define medical event report attend physician event result treatment change , discontinuation study medication prolong hospitalization .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients moderate severe COPD exacerbation older 40yearsold A smoking history least 10packyears Requiring hospitalization COPD exacerbation Presence asthma , allergic rhinitis , atopy systemic disease ( diabetes mellitus hypertension ) Exposed systemic corticosteroid precede month use 1,500 microg/d inhale beclomethasone equivalent Admission intensive care unit ( pH &lt; 7.30 and/or PaCO2 &gt; 70 mm Hg , and/or PaO2 &lt; 50 mm Hg despite supplemental oxygen ) If specific cause exacerbation , pneumonia , pneumothorax , heart failure , diagnose .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>COPD exacerbation</keyword>
	<keyword>Nebulized budesonide</keyword>
	<keyword>Parenteral steroid</keyword>
</DOC>